Stem cells regrow long bones – WNDU-TV

People who suffer catastrophic breaks to their long leg bones usually face multiple surgeries, and all too often, amputation.

Scientists at the University of Arizona have been working for more than 20 years to improve the treatment protocol.

Now, they're using a patient's own fat and 3D printing to regrow long bones.

Yudith Burreal broke her leg when an ATV rolled on her a year ago.

"It was completely missing. They didn't know, it was a big chunk of my bone. It was my tibia bone," she recalled.

Her doctors used her bone and marrow to fix the break. But Burreal ended her plans to go into the military, believing her leg wouldn't support her in training.

University of Arizona researchers are developing a way to fix broken long bones with stem cells, a 3D-printed scaffold and a sensor to monitor exercise that helps bones heal.

"If we can fill our scaffold with these cells, the bone will start to form throughout the length of the scaffold," Dr. John A. Szivek explained.

Stem cells are multiplied in a lab and run with calcium particles through the scaffold between the bone ends. A rod holds it in place for six to nine months. The bone grows in and around the scaffold.

"Lately, we have been successful with removing all of the supporting hardware and showing that supporting the bone that we're regrowing is actually functional tissue, to show that it does not need any additional orthopedic hardware in order to function," Dr. David Margolis said.

This work is funded by a $2 million grant from the United States Department of Defense.

"We believe that using this type of approach could regrow the bones for the soldiers, and they would be able to return to active military service," Szivek said.

Researchers will report the recent success they've had with procedures on sheep to the Food and Drug Administration. If the agency accepts it, a Phase 1 trial of fewer than 10 people could start soon at Banner-University Medical Center in Phoenix.

MEDICAL BREAKTHROUGHSRESEARCH SUMMARYTOPIC: STEM CELLS REGROW LONG BONESREPORT: MB #4630

BACKGROUND: Long bones include the humerus, radius, ulna, femur, tibia and fibula. Fracturing one of these bones can result in an acute, comminuted, or stress fracture. Acute fractures have a dramatic presentation, whereas a stress fracture is not as noticeable and a little more subtle. A comminuted fracture is when the bone is broken down into many little pieces. Normally it takes a massive force to break a long bone, like a car or motorcycle accident. Most car or motorcycle accidents cause a comminuted fracture. Sports injuries like falling while skiing or running into someone during a soccer or football game can also result in the breaking of a long bone. (Source: https://www.texashealth.org/thpg/texas-foot-ankle-orthopedics/conditions-we-treat/lower-extremity-trauma/long-bone-fracture & https://bestpractice.bmj.com/topics/en-us/386)

TREATMENT: Treatments include surgical and non-surgical treatments depending on a patient's health and severity of the fracture. Initial treatment may involve your physician applying a splint to provide comfort and support. Another non-surgical method is a cast and functional brace. Surgical treatment is needed if the patient has an open fracture with wounds that need monitoring or if the fracture never healed after a non-surgical treatment. Surgical procedures include intramedullary nailing, plates and screw, and external fixation. (Source: https://www.texashealth.org/thpg/texas-foot-ankle-orthopedics/conditions-we-treat/lower-extremity-trauma/long-bone-fracture)

REGROWING BONES: John A. Szivek, PhD, Professor, Orthopaedic Surgery, William and Sylvia Rubin Chair of Orthopedic Research, Director, Robert G. Volz Orthopedic Research Laboratory, and Senior Scientist at the Arizona Arthritis Center explains how stem cells are helping regrow bones so that patients do not have to use cadaver bone to replace what was damaged. "The way we're doing that is we start off with creating what's called a scaffold. The scaffold is just a template. That template will help that new bone form in the right shape and structure. And we fill these scaffolds for the patients with their own stem cells. We call them adult stem cells. And we extract those stem cells from the patient's own fat," said Szivek. He adds that there are more benefits to this than former procedures, saying, "The advantage of doing that is there's no rejection potential because we're using the person's own cells. And the other advantage is that if we can fill our scaffold with these cells, the bone will start to form throughout the length of that scaffold." (Source: John Szivek, PhD)

Excerpt from:
Stem cells regrow long bones - WNDU-TV

The Basics of Stem Cell Transplantation – Curetoday.com

Many patients with blood cancers may be candidates for autologous or allogeneic transplant.

But how do patients know if its the right option for them? And which type is best? These questions can be answered by speaking with experts at a transplant center upon referral from a treating physician, according to Dr. Sergio Giralt, chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center in New York City.

Giralt addressed a group of patients during a Sept. 18 Lunch and Learn hosted by the National Bone Marrow Transplant Link and sponsored by the Leukemia & Lymphoma Society. Also speaking during the hour-long discussion was Jacey Walsh, who is in remission following an acute lymphoblastic leukemia (ALL) diagnosis and undergoing chimeric antigen receptor (CAR)-T cell therapy, a type of immunotherapy, in March.

If a patient is a candidate, the team will then decide which transplant is best. Two options are available, autologous, which uses the patients own stem cells, or allogeneic, which involves stem cells that come from a donor, such as a family member who may be a match. If a family match isnt found, an unrelated donor can be recognized through a registry list.

Each of us have 10 or 12 HLA proteins that half of them come from your father and half from your mother. If your brother or sister happens to inherit those same types, you have a match within the family, Giralt said.

Recently, he explained, researchers from Johns Hopkins found a way to conduct transplants using mismatched donors along with the chemotherapy medication cyclophosphamide. So in 2019, everyone should have a match, Giralt said.

The most common indication for an autologous transplant is multiple myeloma. For allogeneic, its acute myeloid leukemia and myelodysplastic syndromes.

The second phase is what they call the low count phase. This is a result of high-doses of chemotherapy and radiation. The patients bone marrow goes down to zero and the cells of the donor or the cells of the patient take 10 to 20 days to recover to normal levels, he said. During this time, patients may feel tired. They may require blood transfusions, intravenous nutrition and hydration and need careful observation in case of any infections.

Phase three is the transition phase where patients move from daily check-ins with their team to two to three visits a week until their counts recover.

Since the immune system is weak, transplant recipients need to be continuously monitored. This is part of the fourth phase, Giralt said.

And finally, phase five is after the first year when a patients immune system is usually strong enough. They will then be revaccinated with the shots received during childhood. This is the part where patients need to take ownership of their own health care, Giralt said. Survivorship care is essential for long-term healthy living. Follow good nutrition, maintain a good exercise level and quit tobacco use if they use, he advised. Patients should also watch for cardiovascular disease and keep cholesterol and blood pressure under control.

With improvements to stem cell transplant, life threatening conditions have been brought down to less than 15%, Giralt explained.

Walsh received CAR-T cell therapy earlier this year after relapsing several times since her April 2013 ALL diagnosis. She failed two traditional therapies and was accepted into a clinical trial in March at the University of Chicago close to home. She received her modified T cells on April 4 and is now considered in remission.

Although the therapy is associated with serious side effects, such as cytokine release syndrome and neurotoxicity, the married mother of two didnt experience them, for which she feels fortunate. A few days after her infusion, she came down with a 104 fever and began to experience confusion. But that subsided within a few days, Walsh said.

In the hospital, I made sure to walk every day, she said. I asked a lot of questions to the doctors and nursing staff because they were really the only ones that I had as a resource to what was going to happen to me.

Despite success with her CAR-T treatment, Walsh said she still struggles with anxiety over the possibility of her cancer returning a common concern among many patients and survivors but has found support through her family, doctors and a therapist.

Originally posted here:
The Basics of Stem Cell Transplantation - Curetoday.com

Potential Treatment for Traumatic Brain Injury Receives Regenerative Advanced Therapy Designation – Drug Topics

The FDA has granted investigational product SB623 from SanBio a Regenerative Medicine Advanced Therapy (RMAT) Designation as a result of recent clinical evidence.

SB623 is a proprietary, cell-based investigational product being tested for effectiveness in treating different neurological conditions. The recent RMAT designation result of new clinical evidence from the Phase 2 Study of Modified Stem Cells in Traumatic Brain Injury Trial (STEMTRA).

The drug candidate is reportedly made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification, according to a statement from SanBio. When implanted directly into injured nerve tissue in the brain, SB623 is expected to trigger natural regenerative abilities that will recover lost motor functions.

Trending: Side Effects of the Shingles Vaccines

In the study that led to this new designation, 61 patients between the ages of 18-75, 12 months post-TBI, with a Glasgow Outcome Scale Extended Score of 3-6 were included from 13 surgical and 18 assessment sites in the U.S, Japan, and the Ukraine. The primary endpoint of the study was the mean change from baseline in Fugl-Meyer Motor Scale (FMMS), which measures the changes in motor impairment at six months.

The study met its primary endpointpatients treated with SB623 achieved an average of an 8.3-point improvement from baseline in FMMS at 23 weeks (p=0.040). 39.1% of patients achieved a 10 or more-point improvement compared to one control patient. No new safety signals were identified. The most common adverse events reported were headaches.

TBIs are one of the most common health conditions worldwide that often cause long-term complications or death. We look forward to working with the FDA on a potentially accelerated clinical development program to address this serious unmet medical need, Bijan Nejadnik, MD, Chief Medical Officer and Head of Research says in astatement.

The Regenerative Medicine Advanced Therapy Designation is reserved for new regenerative medicine therapies intended to treat, reverse, or cure a serious condition and is granted to those investigational products whose clinical evidence indicates the therapy as the potential to address unmet medical needs. The designation also offers sponsors the eligibility for expedited development and regulatory review, as well as earlier and more frequent consultation with the FDA and potential for Priority Review and Accelerated Approval.

According to a release, SanBio expects a phase 3 trail for SB623 to begin after January 2020.

Read more:
Potential Treatment for Traumatic Brain Injury Receives Regenerative Advanced Therapy Designation - Drug Topics

What Is Lab Meat and Is It Vegan? – LIVEKINDLY

Cultured meat also called lab-grown, cell-based, and clean meat could be on dinner tables sooner than once thought. The futuristic cellular agriculture industry is only becoming busier and some say lab meat could be available as soon as 2021.

Lab-grown meat is produced by in vitro cultivation of animal cells. Cellular agriculturists collect a small sample of cells from an animal. These can come from swabbing skin tissue, a feather, etc. The cells must have a rapid rate of proliferation, like embryonic stem cells, adult stem cells, myosattelite cells, or myoblasts.

The cells are placed into a nutrient-rich solution, called a growth medium, in a controlled cultivator. This causes the stem cells to act as they would if they were still in the animals body to multiply, ideally quickly and into high densities.

The result is an edible product that looks, cooks, and tastes like animal meat because, biologically, it is animal meat. The major difference is that an animal does not need to be killed to make it.

Lab-grown meat is meat, meaning it is not vegan. However, the concept may create a loophole for some due to the fact that it can be made without the slaughter of animals.

Not all lab-grown meat production is free from animal use. Dutch scientist Mark Post, who presented the worlds first lab-grown burger at a press conference in 2013, grew cells in an animal-based broth to make his clean meat patty.

He said the most efficient method of cellular agriculture involves the slaughter of animals. Eventually my vision is that you have a limited herd of donor animals in the world that you keep in stock and that you get your cells from there, Post told The Telegraph.

Fetal bovine serum (FBS) poses an issue for vegans interested in lab-grown meat. FBS comes from the blood of a cow fetus and its the most widely used serum-supplement in the industry for eukaryotic cells.

However, some producers, like food tech company JUST, make a point of keeping the entire process cruelty-free. In a video, JUST shows how it developed its lab-grown chicken. For those very first cells, it was important to us how we got those cells, not just that we got the cells, JUST said. We came up with the idea to use one feather from the single best chicken that we could find.

The team waited for the chicken, whose name is Ian, to naturally drop a feather. The researchers then collected cells from this feather, enabling Ian to live on unharmed, but significantly important to the cause. The JUST team feasted on real chicken nuggets while Ian wandered around their feet, alive and well.

Ryan Bethencourt co-founder of the worlds leading life science accelerator, IndieBio believes lab-grown meat can bridge the gap between peoples hunger for meat and their desire to do less harm. The aim is to ensure that people keep eating what they love, but to produce it in a way so its not damaging the planet, Bethencourt, who is a vegan, said to the Guardian.

Conventional meat comes with its risks. In 2015, the World Health Organization (WHO) named red meat a Group 2 carcinogen, meaning it probably causes cancer in humans. WHO placed processed meat like bacon in the Group 1 category, meaning it is carcinogenic to humans. Asbestos and tobacco smoking are also in this category.

Post believes lab-grown meat could be safer for consumption than traditional meat. The creator of the first clean meat burger said to The Atlantic, We gain greater control over what the meat consists of, for example, its fat content.

And the reduction in the number of farmed animals reduces the chance of zoonosis, he added, referring to infectious diseases that can be passed from animals to humans.

JUST holds a similar view. It said in its video, One of the biggest points of comparison between what were doing and the old way of doing things is food safety.

JUSTs video displays a list of the risks associated with conventional meat, including salmonella, swine flu, giardia, fecal contamination, campylobacter, mad cow disease, foot-and-mouth disease, and avian chlamydiosis. It points out that clean meat carries none of these risks. And when you make that comparison, the difference is staggering, the company says.

Physician Neal Barnard, founding president of the Physicians Committee for Responsible Medicine (PCRM), believes lab-grown meat could be fortified to include extra nutrients like B12, in the same way vitamin D is added to orange juice.

The FDA and the USDA announced in March that they have established a framework to regulate clean meat. Its still in its preliminary stages but that hasnt curbed interest in the concept of clean meat. A study released by The Good Food Institute found that 66 percent of Americans are open to eating meat made in a lab.

Five food companies working within the cellular agriculture industry recently banded together to form the Alliance for Meat, Poultry & Seafood Innovation (AMPS Innovation).

AMPS Innovation aims to educate consumers and stakeholders about the industry and look at effective marketing for their products. The companies are also working with the government to establish a regulatory framework.

The founding members include Fork & Goode, JUST, and Memphis Meats, as well as cell-based seafood producers BlueNalu and Finless Foods. Representatives from these companies have met once a week for the last year to discuss obstacles faced by the industry.

The alliance has formed at an apt time, suggests Lou Cooperhouse, CEO of BlueNalu. This industry is maturing and is a lot more near-term than was thought of in the last year or in the past, Cooperhouse said in a statement. This is not something that is 10 years away. It is something that is short-term.

Lab-grown meat is not commercially available yet, but its launch may not be far off.

A recent report by global consultancy AT Kearney stated that by 2040, most of the meat people eat will not come from slaughtered animals. Sixty percent of meat will be either plant-based or cultivated in a lab.

The large-scale livestock industry is viewed by many as an unnecessary evil, the report said. With the advantages of novel vegan meat replacements and cultured meat over conventionally produced meat, it is only a matter of time before they capture a substantial market share.

It later added, Cultured meat will win in the long run.

Traditional animal agriculture leaves an undeniable mark on the planet. Its resource-intensive and generates huge amounts of greenhouse gas emissions. The United Nations Environment Programme (UNEP) named meat the worlds most urgent problem, saying that using animals for food has brought us to the verge of catastrophe.

The greenhouse gas footprint of animal agriculture rivals that that of everycar, truck, bus, ship, airplane, and rocket shipcombined, UNEP said. There is no pathway to achieve the Paris climate objectives without a massive decrease in the scale of animal agriculture.

Swapping to lab-grown meat could alleviate some of this damage. The CEO of Memphis Meats Uma Valeti said to the Guardian, If the US switched to Memphis Meats beef, we would expect the greenhouse gas reduction to be like taking almost 23m cars off the road. One burger could save the amount of water used in 51 showers.

Tim Noakesmith the founder of VOW, which is working on lab-grown kangaroo meat believes cell-based meat could help feed the worlds growing population. Its pretty insane, but its super important, its incredibly important, he said to Nine News. Weve reached the scale capacity in terms of creating food using traditional animal agriculture and we see that meat consumption is going to be rising and rising over coming decades.

VOW says its lab-grown kangaroo meat could be in supermarkets by the end of 2022. Its also speaking with top-tier chefs in Australia to explore the incorporation of its product into meals.

Other lab meat producers have similar goals. Japanese startup IntegriCulture Inc. wants to see its slaughter-free foie gras served in restaurants by 2021 and on the consumer market by 2023.

CEO of JUST Josh Tetrick took to Twitter in October to tease the launch of JUSTs lab-grown chicken nuggets. The company hasnt announced concrete plans, but Tetrick took the cruelty-free nuggets to the UK in January so that English TV presenter Helen Skelton-Myler could taste-test them. Tetrick explained, It is a nugget that didnt require killing a chicken and thats the way all meat should be. We dont need to choose between veggie burgers and a real burger.

Even the meat industry is clocking on to the notion. Agricultural giant Cargill invested in lab-grown meat company Aleph Farms earlier this year. Cargill, which controls more than 20 percent of Americas domestic meat market, has also invested in Memphis Meats.

Major meat producer Tyson Foods has also invested in Memphis Meats. Its also an investor in Israeli clean meat startup Future Meat Technologies. Justin Whitmore, Executive Vice President, Corporate Strategy and Chief Sustainability Officer of Tyson Foods, spoke about the move at a panel event in 2018. We dont want to be disrupted, he said.We want to be part of the disruption.

Summary

Article Name

What Is Lab Meat and Is It Vegan?

Description

Cultured meat -- also called lab-grown, cell-based, and clean meat -- could be available as soon as 2021. But what is lab meat? And is lab meat vegan?

Author

Jemima Webber

Publisher Name

LIVEKINDLY

Publisher Logo

Read this article:
What Is Lab Meat and Is It Vegan? - LIVEKINDLY

Stem Cells Market Will Generate New Growth Opportunities in the upcoming year – OnYourDesks

HTF MI recently Announced Global Stem Cells study with 100+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on Stem Cells. Global Stem Cells research allows you to get different methods for maximizing your profit. The research study provides estimates for Global Stem Cells Forecast till 2025*. Some of the Leading key Companys Covered for this Research are CCBC, Vcanbio, Boyalife & Beikebiotech.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market.

Click to get Global Stem Cells Market Research Sample PDF Copy Here @:https://www.htfmarketreport.com/sample-report/928542-global-stem-cells-market-3

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.The global Stem Cells market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.

Global Stem Cells Research for a Leading company is an intelligent process of gathering and analyzing the numerical data related to services and products. This Research Give idea to aims at your targeted customers understanding, needs and wants. Also, reveals how effectively a company can meet their requirements. The market research collects data about the customers, marketing strategy, competitors. The Stem Cells Manufacturing industry is becoming increasingly dynamic and innovative, with more number of private players entering the industry.

Important Features that are under offering & key highlights of the report:

1) Who are the Leading Key Company in Global Stem Cells market space?

Following are list of players that are currently profiled in the report CCBC, Vcanbio, Boyalife & Beikebiotech

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.2) What will the market size be in 2025 and what will the growth rate be?In 2019, the Global Stem Cells market size was xx million USD and it is expected to reach USD xx million by the end of 2025, with a CAGR of xx% during 2019-2025.

3) By What Applications & Types Does Market Study is Segmented:

The study is segmented by following Product Type: , Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell & Other

Major applications/end-users industry are: Diseases Therapy & Healthcare

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2018 currency rates.

To comprehend Global Stem Cells market dynamics in the world mainly, the worldwide Stem Cells market is analyzed across major regions. HTF MI also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/928542-global-stem-cells-market-3

Competitive Analysis:The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as CCBC, Vcanbio, Boyalife & Beikebiotech includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.Research Parameter/ Research Methodology

Primary Research:The primary sources involves the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Check for Discount, Offers ranging from 15% to 35% on Immediate Purchase on different Licenses @https://www.htfmarketreport.com/request-discount/928542-global-stem-cells-market-3

In this study, the years considered to estimate the market size of Global Stem Cells are as follows:History Year: 2013-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025

Key Stakeholders in Global Stem Cells Market:Global Stem Cells ManufacturersGlobal Stem Cells Distributors/Traders/WholesalersGlobal Stem Cells Subcomponent ManufacturersIndustry AssociationDownstream Vendors

**Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Buy this research @https://www.htfmarketreport.com/buy-now?format=1&report=928542

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter|Google+

View post:
Stem Cells Market Will Generate New Growth Opportunities in the upcoming year - OnYourDesks

Researchers Use CRISPR to Correct Mutation in Duchenne Muscular Dystrophy Model – Technology Networks

Duchenne muscular dystrophy (DMD) is a rare but devastating genetic disorder that causes muscle loss and physical impairments. Researchers at the University of Missouri School of Medicine have shown in a mouse study that the powerful gene editing technique known as CRISPR may provide the means for lifelong correction of the genetic mutation responsible for the disorder.

Children with DMD have a gene mutation that interrupts the production of a protein known as dystrophin. Without dystrophin, muscle cells become weaker and eventually die. Many children lose the ability to walk, and muscles essential for breathing and heart function ultimately stop working.

"Research has shown that CRISPR can be used to edit out the mutation that causes the early death of muscle cells in an animal model," said Dongsheng Duan, PhD, Margaret Proctor Mulligan Professor in Medical Research in the Department of Molecular Microbiology and Immunology at the MU School of Medicine and the senior author of the study. "However, there is a major concern of relapse because these gene-edited muscle cells wear out over time. If we can correct the mutation in muscle stem cells, then cells regenerated from the edited stem cells will no longer carry the mutation. A one-time treatment of the muscle stem cells with CRISPR could result in continuous dystrophin expression in regenerated muscle cells."

In collaboration with other MU colleagues and researchers from the National Center for Advancing Translational Sciences, Johns Hopkins School of Medicine and Duke University, Duan explored whether muscle stem cells from mice could be efficiently edited. The researchers first delivered the gene editing tools to normal mouse muscle through AAV9, a virus that was recently approved by the U.S. Food and Drug Administration to treat spinal muscular atrophy.

"We transplanted AAV9 treated muscle into an immune-deficient mouse," said Michael Nance, a MD-PhD program student in Duan's lab and the lead author of the paper. "The transplanted muscle died first then regenerated from its stem cells. If the stem cells were successfully edited, the regenerated muscle cells should also carry the edited gene."

The researchers' reasoning was correct, as they found abundant edited cells in the regenerated muscle. They then tested if muscle stem cells in a mouse model of DMD could be edited with CRISPR. Similar to what they found in normal muscle, the stem cells in the diseased muscle were also edited. Cells regenerated from these edited cells successfully produced dystrophin.

"This finding suggests that CRISPR gene editing may provide a method for lifelong correction of the genetic mutation in DMD and potentially other muscle diseases," Duan said. "Our research shows that CRISPR can be used to effectively edit the stem cells responsible for muscle regeneration. The ability to treat the stem cells that are responsible for maintaining muscle growth may pave the way for a one-time treatment that can provide a source of gene-edited cells throughout a patient's life."

With more study, the researchers hope this stem cell-targeted CRISPR approach may one day lead to long-lasting therapies for children with DMD.

Reference: Nance et al. 2019.AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice. Molecular Therapy.DOI: https://doi.org/10.1016/j.ymthe.2019.06.012.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original:
Researchers Use CRISPR to Correct Mutation in Duchenne Muscular Dystrophy Model - Technology Networks

SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits…

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI). The designation is based on clinical results of SB623 including the Phase 2 Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) trial.

Created under the 21st Century Cures Act, the RMAT designation is reserved for a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious condition, and clinical evidence indicates that the therapy has the potential to address unmet medical needs for such disease or condition. Similar to the Breakthrough Therapy designation, the RMAT designation offers sponsors of cell and gene therapies eligibility for expedited development and regulatory review of their product candidate, including earlier and more frequent consultation with the FDA, and the potential for Priority Review and Accelerated Approval.

The RMAT designation for SB623 is an important regulatory milestone for SanBio as we investigate it as a treatment option for patients with chronic neurological motor deficits resulting from a traumatic brain injury, said Bijan Nejadnik, M.D., Chief Medical Officer and Head of Research. TBIs are one of the most common health conditions worldwide that often cause long-term complications or death. We look forward to working with the FDA on a potentially accelerated clinical development program to address this serious unmet medical need.

The RMAT designation augments the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare of Japan.

About SB623SB623 is a proprietary, cell-based investigational product made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brains natural regenerative ability to recover lost motor functions.

SanBio expects to initiate a Phase 3 trial for SB623 for the treatment of chronic neurological motor deficits secondary to TBI by the end of the fiscal year ending January 31, 2021. SB623 is also currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke.

About the Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) TrialSTEMTRA was a 12-month, Phase 2, randomized, double-blind, surgical sham-controlled, global trial evaluating the efficacy and safety of SB623 compared to sham surgery in patients with stable chronic neurological motor deficits secondary to TBI. In this study, SB623 cells were implanted directly around the site of brain injury.

To be eligible for this trial, patients (ages 18-75) must have been at least 12 months post-TBI and had a Glasgow Outcome Scale extended (GOS-E) score of 3-6 (e.g., moderate or severe disability). Patients must also have been able to undergo all planned neurological assessments and had no seizures in the prior three months. The primary endpoint was mean change from baseline in Fugl-Meyer Motor Scale (FMMS) score which measures changes in motor impairment at six months. The STEMTRA trial enrolled 61 patients from 13 surgical and 18 assessment sites in the U.S., Japan and Ukraine.

In this study, SB623 met its primary endpoint, with patients treated with SB623 achieving an average 8.3 point improvement from baseline in the FMMS, versus 2.3 in the control group, at 24 weeks (p=0.040). Of patients treated with SB623, 18 (39.1%) reached a 10 or more point improvement of FMMS compared to one control patient (6.7%; p=0.039). No new safety signals were identified. The most commonly reported adverse event were headaches.

About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)SanBio Group is a regenerative medicine company with cell-based products focused on neurological disorders in various stages of research, development and clinical trials. The Companys lead asset, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from ischemic stroke and traumatic brain injury. SanBio has received a Japanese marketing license for regenerative medicine products from the Tokyo Metropolitan Government, and plans to begin marketing regenerative medicine products in Japan by the end of the fiscal year ending January 31, 2021. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at https://sanbio.com.

Go here to see the original:
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits...

Cell Banking Outsourcing Market is slated to grow rapidly in the coming years – ScoopJunction

The new report has been added to Reportocean.coms offering. For more info click here @https://www.reportocean.com/industry-verticals/details?report_id=5073

The global cell banking outsourcing industry report offers an in-depth analysis of major driving factors, segments, regions & countries and key players in the market. Moreover, the cell banking outsourcing market report 2019 also outlines the competitive scenarios across different geographies along with key developments that include:

Mergers and Acquisitions

New Product or Services Development

R&D Activities

Thus, giving insights to the market players about the major regions gaining traction.

The study also provides a comprehensive perspective of major segments in the global cell banking outsourcing market in all the major regions and countries. The study offers in-depth regional analysis over the forecast period along with the current market scenarios and situations. The major regions analyzed in the study include:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The cell banking outsourcing industry report also includes additional information about other factors such as drivers, restraints and challenges faced by this market along with an overview for each mentioned segment in the study.

The worldwide cell banking outsourcing market 2019 research report provides a deep-dive analysis on the present market situation and future market trends. The analysis provided in the report help the manufacturers, companies, service providers etc. as a major guiding factor for decision making and analyzing the current and future market situations. The report also analyzes the major players operating in the market.

Why to purchase this report

1. The study would provide an in-depth analysis on the current and future market trends

2. Analysis on both global, regional and country lever markets

3. Key strategic initiatives taken by major players operating in the market along with ranking analysis for the key players

4. Analysis based on historical information along with the current trends to estimate the future of the market

5. Analysis of the impact of constantly changing global market scenarios on the market

Global Cell Banking Outsourcing Market Major highlights of the Table of Contents of the study:

>Market Overview & Summary

>Market Dynamics

-Drivers

-Restraints

-Opportunities

-Challenges

-Market Share Analysis

-PORTERS Analysis

-PESTEL Analysis

-Value-chain Analysis

> Global Cell Banking Outsourcing Market by Segment 1

Sub Segment type 1

Sub Segment type 2

> Global Cell Banking Outsourcing Market by Segment 2

Sub Segment type 1

Sub Segment type 2

> Global Cell Banking Outsourcing Market by Region

-North America

U.S.

Canada

-Europe

UK

France

Germany

EXECUTIVE SUMMARY OF THE STUDY:

Continue

View Full Report Detail and Table of Content athttps://www.reportocean.com/industry-verticals/details?report_id=5073

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=5073

EXECUTIVE SUMMARY OF THE STUDY:

The global cell banking outsourcing market is anticipated to reach USD 4,366.9 Million by 2025 according to a new report published by Polaris Market Research. In 2017, on the basis of type, master cell banking segment capture the largest market shares in terms of revenue and hold the major share in the market. Regionally, North America accounted for the major share in the global cell banking outsourcing market.

The global Cell Banking Outsourcing market growth is primarily driven by the rising number of clinical trials which has helped in unmasking the potential of stem cells and their relative applications. Similarly, awareness for stem cell banking across multiple developing countries, and increasing governments initiatives that promote the awareness for stem cell isolation & its related benefits to influence the market growth during the forecast period. Rising research activities related to stem cell applications are expected to support the market growth during the forecast period. Furthermore, increase in the average life expectations due to advanced medical research and improved general lifestyle of the population, and straightforward regulations for the stem cell researchers is expected to create significant potential for this market in coming years. While, increasing number of adipose tissue banking has also become one of the major opportunities.

The global cell banking outsourcing market is segmented on the basis of Type, Product type, cell type and phase. On the basis of type, the market is categorized into Master Cell Banking, Viral Cell Banking, and Working Cell Banking. On the basis of product type, the market is segmented into Cord Cell Banking, Adult Stem Cell Banking, IPS Stem Cell Banking, Embryonic Stem Cell Banking, and IPS Stem Cell Banking. The cell type is further categorized into Stem Cell and Non-Stem Cell. The phase is segmented into bank storage, bank preparation and bank characterization & testing. The bank storage is furt..continue..

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=5073

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or country-based analysis can be provided as a part of customization

Follow us on:

Facebook: https://www.facebook.com/reportocean

Twitter: https://twitter.com/reportocean

LinkedIn: https://in.linkedin.com/company/reportocean

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Sandeep SinghEmail:sales@reportocean.com

Original post:
Cell Banking Outsourcing Market is slated to grow rapidly in the coming years - ScoopJunction

7th Annual Miracles for Myeloma 5K Run/Walk – New Jersey Hills

The 7TH ANNUAL MIRACLES FOR MYELOMA 5K RUN/WALK will take place on Saturday, September 21, 2019. Last year, at the 6th Annual Miracles for Myeloma Run/Walk, over $80,000 was raised in pursuit of the cure for Multiple Myeloma, and a Senior Brian D. Novis Research Grant was awarded by the International Myeloma Foundation. The Grant was presented to the researcher helping to find the cure, at the American Society of Hematologist Conference last December 2018! It is once again the goal of the Miracles for Myeloma 5k Run/Walk, to raise awareness and money, in the ongoing fight against this deadly disease. In all, over the past 6 years, over $500,000 has been raised. Multiple Myeloma is the incurable cancer of the plasma cells in the bone marrow, which attacks and destroys bone.

The 7TH ANNUAL MIRACLES FOR MYELOMA 5K RUN/WALK will be held at Oak Ridge Park, 136 Oak Ridge Road, in Clark, New Jersey. The course is staged entirely within the park on paved paths, and is a USATF Certified Course. People of all ages are encouraged to participate in this community wide fundraiser. Strollers and dogs on leashes, are welcome, and the course is wheelchair friendly. Enjoy giveaways, post-race refreshments, childrens activities, and much more!!! Following the course through the Remembrance Path, where people who are living with cancer are honored, and people who have passed away from cancer are remembered, is an emotional as well as an inspirational moment.

The entry fee is $30 for adult runners and walkers, and after September 1, 2019, that fee will increase to $35. Children 12 and under are $20. Online registration ends on September 17, 2019, and runners/walkers may also register the day of the race for $40. Check-in time is between 8:00 am and 9:15 am, with the runners beginning at 9:30 am and the walkers beginning at 9:45 am. All donations will be excepted through December 18, 2019.

The co-founders of the race are Clark residents Ron and Sheree Pask, and Westfield resident Gina Klemm. Sheree is a Multiple Myeloma survivor and is a teacher at The Presbyterian Nursery School in Westfield. Sheree was diagnosed in 2007 and has undergone chemotherapy, two stem cell transplants and is currently in remission. Ginas brother, Frank Guarino, passed away from Multiple Myeloma in 2012, after being diagnosed in 2011, he also underwent chemotherapy and two stem cell transplants. Frank was an avid runner, and after Gina met Sheree at her daughters preschool, their common bond was formed and the MIRACLES FOR MYELOMA 5K RUN/WALK was organized.

As International Myeloma Foundation founder, Brian Novis said

ONE PERSON CAN MAKE A DIFFERENCE TWO PEOPLE CAN MAKE A MIRACLE

Join us on September 21, 2019 and help make miracles happen!!

TO REGISTER, PLEASE VISIT http://give.myeloma.org/site/TR?fr_id=1770&pg=entry

OR

CONTACT RON PASK IF YOU HAVE QUESTIONS AT

miracles4mm@comcast.net

OR

732-574-9182

See the original post:
7th Annual Miracles for Myeloma 5K Run/Walk - New Jersey Hills

Religion briefs for Sept. 19 | Community – Petoskey News-Review

Church to host food summit

PETOSKEY More than 6,500 people (11 percent) of Charlevoix and Emmet counties live at or below the poverty level.

In response to this need, dozens of churches and organizations host food pantries and/or offer free community meals throughout the week.

Emmanuel Episcopal Church, 1020 E. Mitchell St., Petoskey, is hosting a food summit from 9 a.m.-noon Saturday, Sept. 28, to bring individuals, churches and organizations together who are passionate about supporting people who are experiencing food insecurity to share best practices and learn about opportunities for collaboration.

Kim Baker, executive director of Manna Food Project, is the keynote speaker. Manna Food Project partners with food pantries, community meal programs and baby/paper pantries throughout Emmet, Charlevoix and Antrim counties.

In addition, there will be workshops on best practices in operating food pantries, community meals and grant writing.

Members of the community are invited to attend this summit, whether you are already involved in a food-based ministry or initiative, or if you would like to learn how you might become involved.

If you are interested in attending the summit or seeking more information, contact the Emmanuel Episcopal Church office at (231) 347-2350.

Community breakfast offered

ALANSON There will be a community breakfast from 9:30-10:45 a.m. Sunday, Sept. 22, at the Alanson Church of the Nazarene, 7489 Mission Road.

The meal is free of charge and features biscuits and gravy, scrambled eggs, waffles, juice and coffee.

There also will be face painting for the kids.

The breakfast is sponsored by the churchs Sunday School.

For more information, call the church at (231) 548-5462.

Stem cell therapies discussed

BOYNE CITY A discussion about stem cell therapies will begin at 6:30 p.m. Sunday, Sept. 22, at Lifetree Caf.

The program, Stem Cells: The Miracle Cure You May Be Missing Out On, includes a film featuring a regenerative stem cell procedure as well as an interview with Dr. Christopher Centeno, who performs orthopedic procedures using adult stem cells in both the U.S. and in an offshore clinic.

Over the next 20 to 30 years, many drugs we use today will be replaced by stem cells from our own bodies, or cells mass-produced in labs, said Centeno, who notes that the shift in medicine puts at risk much of the $300 billion prescription drug market.

Centeno, who uses stem cells as an alternative to joint replacement and to treat tendon, ligament and bone pain, wonders if concerns about lost revenue have prompted the domestic ban of some procedures that are available in other countries. This program provides insights into the ongoing debate.

The hourlong program is free of charge.

Lifetree Caf is in the First Presbyterian Church, 401 S. Park St. Use the Pine Street entrance.

Creation at Risk sermon topic

CHARLEVOIX Greensky Hill Indian United Methodist Church, 08484 Green Sky Hill Road, presents part four in the five-week series, The Season of Creation.

At 10 a.m., Sunday, Sept. 22, the Rev. Jonathan Mays will share a message from Jeremiah 8:18-9:1 entitled, Creation at Risk.

Mark the date for the finale of the series on Sunday, Sept. 29, when the community is invited to bring leashed or caged animals for The Blessing of the Animals ceremony at Greensky Hills outdoor worship space, The Tabernacle.

Also, Greensky Hills annual harvest dinner will be from 4-6:30 p.m., Saturday, Sept. 28, in Susan Hall.

All are welcome for a traditional menu including turkey, mashed potatoes and gravy, stuffing, squash, ham, corn, carrots, string beans, creamed cabbage, applesauce, tomatoes, dinner rolls, pie, coffee, tea and lemonade.

The cost is $12 for adults; $4 for children ages 4-12; and $35 for a family of six or more.

Message looks at anger, harsh words

CHARLEVOIX On Sunday, Sept. 22, the series, Braving the Wilderness, continues at Community Reformed Church.

The title of the message is Carried Anger and Harsh Words and will be based on Matthew 5:21-22.

Sunday morning services are at 8:30 and 10:15 with nursery available at each service.

Worship activities for children preschool through fourth grade are offered during the 10:15 service.

The church is located at 100 Oak St.

Read more:
Religion briefs for Sept. 19 | Community - Petoskey News-Review